Colombo R, Da Pozzo L F, Lev A, Freschi M, Gallus G, Rigatti P
Department of Urology, Scientific Institute H, San Raffaele, Milan, Italy.
J Urol. 1996 Apr;155(4):1227-32.
We evaluated the effectiveness of local bladder hyperthermia and intravesical chemotherapy compared to intravesical chemotherapy alone in the treatment of superficial transitional cell carcinoma.
A new system designed to deliver simultaneously local bladder hyperthermia and intravesical chemotherapy has been developed at our institute. The system consists of a computerized 915 MHz. microwave source that directly heats the bladder walls (within a temperature range of 42.5 to 45.5C) using a transurethral catheter. From February 1989 to December 1993, 52 patients 44 to 81 years old (mean age 64.3) with superficial stages Ta to T1, grades 1 to 3 transitional cell carcinoma of the bladder were selected for neoadjuvant intracavitary treatment. Tumors were left intact as marker lesions. Of the patients 29 were randomly assigned to receive combined neoadjuvant intravesical chemotherapy and local hyperthermia (group 1), while 23 received intravesical chemotherapy alone (group 2). The treatment protocol included multiple sessions performed on an outpatient basis. Mitomycin C (40 mg. in 50 cc distilled water) was used for intravesical chemotherapy in both groups. All patients underwent transurethral resection of residual tumors and of all suspicious areas 7 to 10 days after completion of treatment. Only a complete response was considered for statistical analysis.
A pathological complete response was documented in 19 cases (66%) in group 1 and 5 (22%) in group 2 (chi-square p< 0.01).
According to these preliminary data, microwave induced hyperthermia combined with local intravesical chemotherapy seems to be a feasible, safe and promising approach for neoadjuvant and minimally invasive treatment of superficial bladder cancer.
我们评估了局部膀胱热疗联合膀胱内化疗与单纯膀胱内化疗相比,在治疗浅表性移行细胞癌中的有效性。
我们研究所研发了一种新系统,可同时进行局部膀胱热疗和膀胱内化疗。该系统由一台计算机控制的915兆赫微波源组成,通过经尿道导管直接加热膀胱壁(温度范围为42.5至45.5摄氏度)。从1989年2月至1993年12月,选取了52例年龄在44至81岁(平均年龄64.3岁)、处于Ta至T1浅表阶段、1至3级膀胱移行细胞癌患者进行新辅助腔内治疗。肿瘤作为标记性病变保持完整。其中29例患者被随机分配接受新辅助膀胱内化疗联合局部热疗(第1组),23例患者仅接受膀胱内化疗(第2组)。治疗方案包括在门诊进行多个疗程。两组均使用丝裂霉素C(40毫克溶于50毫升蒸馏水中)进行膀胱内化疗。所有患者在治疗完成后7至10天接受经尿道残余肿瘤及所有可疑区域切除术。仅将完全缓解纳入统计分析。
第1组有19例(66%)记录到病理完全缓解,第2组有5例(22%)(卡方检验p<0.01)。
根据这些初步数据,微波诱导热疗联合局部膀胱内化疗似乎是浅表性膀胱癌新辅助和微创治疗的一种可行、安全且有前景的方法。